Cesca Therapeutics Inc. Announces Management Appointments
February 28, 2017 at 11:00 am
Share
Cesca Therapeutics Inc. announced that it has appointed Ms. Vivian Liu as its Chief Operating Officer and elected Dr. Russell Medford to its board of directors. Ms. Vivian Liu, a member of Cesca’s board of directors since November 2016, has over 20 years of experience in finance, operations and M&A activities for private and public pharmaceutical companies. Prior to joining the company, Ms. Liu was the Managing Director of OxOnc Services Company. Dr. Russell Medford is a Managing Partner of the Salutramed Group, LLC and has extensive private and public company expertise. He is also currently the CEO of healthEgames Inc. and serves as the Executive Chairman of ViaMune Inc.
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.
THERMOGENESIS HOLDINGS, INC. 
